Background: Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III trials comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mechanical heart valves, but variably included patients with other VHD and valve surgeries.
Background: The original non-vitamin K antagonist oral anticoagulant (NOAC) trials in nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies.
With oral vitamin K antagonists and non-vitamin K oral anticoagulants being covered, you'll be able to understand the merits and drawbacks of individual treatments in detail.
Bayer HealthCare announced the initiation of the PIONEER AF-PCI study, a Phase IIIb clinical study of its oral anticoagulant Xarelto...
Safe and effective use of NOACs for stroke prevention in patients with atrial fibrillation
This educational resource is designed to help healthcare professionals diagnose, manage and treat bleeding in patients taking anticoagulants.
The Bristol-Myers Squibb-Pfizer Alliance presented new real-world evidence (RWE) from a sub-analysis of the ARISTOPHANES study comparing the safety and...
The FDA on 29 April 2013 has approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K...
This study aimed to examine the most reliable evidence on the relationship between early menopause and the risk of heart failure and atrial fibrillation.
With changing prescription practice, among other factors, clinicians can expect to see rising numbers of patients with ischemic stroke and pre-existing NOAC therapy. Few data exist regarding a potential impact of NOAC on stroke severity and outcome.